- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cate Lockhart, PharmD, PhD: Upcoming Research From the BBCIC
Cate Lockhart, PharmD, PhD, discusses the research reports the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) plans on releasing in 2020.
Transcript
We have a couple of really exciting projects that we're just gearing up to get going now.
One is another one of these infrastructure projects where we're looking at the data feasibility and the capabilities within our distributed research network administrator claims. It's often difficult to find, to identify, clinical outcomes. And cancer has a very specific set of outcomes that we're interested in. And so we're looking at how can we expand our existing data network, while still keeping the multistakeholder environment intact, to give us the capability to do the same kind of research that we're doing in nononcology products and translate that over into oncology.
So that's an infrastructure project that we're that we're working on now. And we are just launching our first full-scale comparative effectiveness study in the G-CSF [granulocyte colony-stimulating factor] products because we have enough utilization in in the US to allow us to do that. That'll take 18 months or so before we're really finished with that by the time we launch, but that's going to be a really interesting project and, and I think that's going to help define some of our future projects.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
